News

With gratitude and appreciation, the ALS Society of Canada (ALS Canada) acknowledges the significant contributions of four Board members whose terms have come to an end. Thank you to Norma Beauchamp, Catherine Bélanger, Josette Melanson, and Jim Mitrakos for your…

The ALS Society of Canada (ALS Canada) is excited to welcome Dr. Leslie Green, Jude Groves, and Kris Noakes to our Board of Directors. Comprised of leadership volunteers with a variety of backgrounds and expertise, our Board ensures ALS Canada…

Dr. Angela Genge has been working on clinical trials for ALS for years, but there’s still a major hurdle to identifying effective treatments. “We’re still using functional measures to see whether or not something is working,” she said.  This includes…

Garry Zelasek is the type of guy who would give you the shirt off his back. “He’s always been selfless that way,” says his wife, Michelle. “He’s just a very kind-hearted soul who is always putting other people before him.”…

ALS Awareness Month is drawing to a close, but our efforts to create a future without ALS continue year-round. Driven by the ALS community, we look to create connection and impact, sharing the progress towards our mission along the way.…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the June 2022 Research Update, you’ll learn about the progress researchers have made in…

Today, Amylyx Pharmaceuticals, Inc. announced that Health Canada has approved ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c). This means the drug will soon be made available and can be marketed in Canada with certain conditions. Health Canada’s…